- Current report filing (8-K)
August 15 2012 - 4:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported) August 15, 2012
CORTEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
1-16467
|
|
33-0303583
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S Employer
Identification No.)
|
|
|
7700 Irvine Center Drive, Suite 750
Irvine, California
|
|
92618
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (949) 727-3157
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. Results of Operations and Financial Condition.
On August 15, 2012, Cortex Pharmaceuticals, Inc. issued a press release to report its financial results. The press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.
All of the foregoing information, including Exhibit
99.1, is being furnished under Item 2.02 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
|
(a)
|
Financial Statements of Businesses Acquired: None.
|
|
(b)
|
Pro Forma Financial Information: None.
|
|
(c)
|
Shell Company Transactions: None.
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press release of Cortex Pharmaceuticals, Inc. dated August 15, 2012.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CORTEX PHARMACEUTICALS, INC.
|
|
|
|
|
Date: August 15, 2012
|
|
|
|
By:
|
|
/s/ Maria S. Messinger
|
|
|
|
|
|
|
Maria S. Messinger
|
|
|
|
|
|
|
Vice President, Chief Financial Officer and
Corporate Secretary
|
EXHIBIT INDEX
|
|
|
|
|
|
|
Exhibit
Number
|
|
Description
|
|
Sequential
Page No.
|
|
|
|
|
99.1
|
|
Press release of Cortex Pharmaceuticals, Inc. dated August 15, 2012.
|
|
|
5
|
|
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024